Stock analysts at Lifesci Capital cut their FY2025 earnings per share estimates for Astria Therapeutics in a research report ...
8d
Fintel on MSNLifeSci Capital Initiates Coverage of Immunome (IMNM) with Outperform RecommendationFintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Immunome (NasdaqCM:IMNM) with a Outperform ...
Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to ...
7d
Fintel on MSNLifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform RecommendationFintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a ...
LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...
LifeSci Capital initiated coverage of Immunome (IMNM) with an Outperform rating and $20 price target Optimize Your Investment Research with ...
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Molecular Partners AG - Depositary Receipt () (NasdaqGS:MOLN) with a Outperform recommendation. As of March 4 ...
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a Outperform recommendation. As of March 4, 2025, the average one-year price ...
In addition to LifeSci Capital, Zymeworks also received a Buy from J.P. Morgan’s Brian Cheng in a report issued on March 6. However, on March 7, H.C. Wainwright reiterated a Hold rating on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results